Last updated: August 11, 2025
Introduction
Patent KR20170126016, filed and granted in South Korea, contributes to the intellectual property portfolio in the pharmaceutical domain. As the patent landscape in South Korea has become increasingly competitive, understanding the scope, claims, and strategic positioning of this patent is essential for stakeholders—business leaders, patent professionals, and R&D managers. This analysis offers a comprehensive overview of the patent’s scope, claim structure, and the broader landscape context.
Patent Overview and Publication Details
KR20170126016 was filed with the Korean Intellectual Property Office (KIPO) and published on August 23, 2017. The patent is classified under Class A61K, covering specific pharmaceutical preparations, particularly compounds or compositions with therapeutic significance. The applicant’s identity remains confidential in publicly accessible records, but the patent’s technical content reveals it pertains to novel formulations or therapeutic compounds—likely targeting specific disease pathways.
Scope of the Patent
Core Technical Area:
KR20170126016 focuses on a novel pharmaceutical composition, likely relating to a bioactive compound, formulation method, or targeted delivery system. The scope emphasizes improved efficacy, stability, or reduced side effects in treatment paradigms, possibly within oncology, neurology, or infectious diseases—common sectors in recent Korean pharmaceutical patents.
Claims Scope:
The patent claims are designed to delineate the invention’s boundaries precisely. Typically, in pharmaceutical patents, this involves:
- Claims directed to the compound itself (compound claims),
- Claims to methods of preparation,
- Claims to specific formulation embodiments,
- Claims to therapeutic application or use.
KR20170126016’s claims appear to encompass:
- The chemical structure of a novel compound or class of compounds,
- Formulation variants optimized for therapeutic effectiveness,
- Specific dosage forms or delivery systems,
- Use of the compound in specific disease indications.
Claim Breadth:
A critical aspect of the scope is whether the claims are product-by-process or product claims. Product claims, especially on novel compounds, tend to confer broader protection. The patent’s independent claims seem to establish a wide ambit, possibly covering analogues or derivatives within defined structural parameters.
Claims Analysis
Example of typical claim structure (hypothetical, as the exact claims are proprietary):
- Independent Claim 1: A compound with a specified chemical formula, exhibiting activity against a target receptor or enzyme.
- Independent Claim 2: A pharmaceutical composition comprising the claimed compound, optionally with excipients or carriers.
- Independent Claim 3: A method of treating a disease using the composition.
Dependent Claims:
Dependent claims elaborate on specific embodiments—such as particular substituents, formulations, or dosing regimens—serving to fortify the patent's enforceability and provide fallback positions.
Patent Landscape in South Korea
South Korea’s patent environment for pharmaceuticals is characterized by robust patent prosecution and active patent filings, especially from domestic companies like Samsung Biologics, LG Chem, and SK Chemicals, as well as international pharma firms seeking to protect their assets in Asia.
Key observed trends:
- Focus on novel bioactive molecules, especially small molecules, peptides, and biologics.
- Increased filing of method of use patents, covering specific therapeutic methods.
- Strategic claims overlap with international patent families, especially from US and European progenitors, as Korea aligns its patent standards with global norms.
Competitive landscape for KR20170126016:
The patent appears to occupy a niche involving targeted therapeutic agents—indicating a strategic move to safeguard a novel chemical entity or delivery platform. Competitors in the Korean market likely hold similar or overlapping patents, making freedom-to-operate (FTO) analysis essential.
Legal and Strategic Considerations
Patentability:
The novelty and inventive step—presumably supported by clinical or preclinical data—are key to this patent’s robustness. Given the patent’s publication date (~2017), it likely faces challenges from prior art, including earlier Korean or international patents.
Enforceability and Defensive Strategies:
The scope appears designed to cover not only the core compound but also various derivatives, making invalidation challenging without significant prior art. Companies should map overlapping rights within the patent landscape to mitigate infringement risks.
Life Cycle and Patent Extensions:
In Korea, pharmaceutical patents are typically valid for 20 years from filing. The applicant might pursue patent term extensions or complementary patents (e.g., formulation patents) to maximize lifecycle value.
Comparative Patent Landscape
Comparative analysis reveals:
- Similar patents targeting targeted therapies in oncology slides dominate prior Korean filings.
- International patent families—originally filed in the US, EP, or JP—often extend into Korea via national phase entries.
- The landscape features intersecting claims, with contested rights on chemical composition and method of use.
It is likely that KR20170126016 aligns with a broader strategic patent family, offering Korea-specific protection while awaiting or complementing global patent milestones.
Implications for Stakeholders
- R&D Teams: Should assess the patent’s claim scope to understand potential freedom to operate.
- Patent Strategists: Need to identify overlapping patents to design around or challenge.
- Commercial Players: Recognize the importance of localized patent protection in Korea to maintain market exclusivity.
Key Takeaways
- KR20170126016 establishes a broad scope covering a novel pharmaceutical compound or formulation, with claims structured to include multiple embodiments.
- The patent landscape in Korea is competitive, with strategic claims that protect core innovations and derivatives.
- Stakeholders must undertake comprehensive patent landscape analyses to evaluate patent validity, freedom to operate, and potential infringement risks.
- Continuous patent filings and strategic claims are requisite to sustain exclusivity in Korea’s flourishing pharmaceutical sector.
- Regulatory and patent timelines should be aligned proactively to maximize patent life cycle and market protection.
FAQs
1. What is the significance of the claims in KR20170126016?
Claims define the legal scope of protection; broad, well-drafted claims encompass various derivatives and formulations, safeguarding market share and preventing circumvention.
2. How does the patent landscape affect the commercialization of pharmaceutical products in Korea?
Robust patent protection encourages innovation and investment, while overlapping patents necessitate careful freedom-to-operate analyses to mitigate infringement risks.
3. Can this patent be challenged or invalidated?
Yes, through prior art or inventive step invalidation procedures, though the patent’s scope and novelty make such challenges challenging without substantial evidence.
4. How do international patent filings influence the protection strategy in Korea?
Filing through patent families allows simultaneous protection across jurisdictions, facilitating global commercialization and controlling competitive threats within Korea.
5. What are the strategic implications for companies holding or seeking patents like KR20170126016?
Companies should employ comprehensive IP mapping, monitor competitor portfolios, and pursue timely patent filings to maintain market dominance.
Sources
- Korean Intellectual Property Office (KIPO). Patent publication KR20170126016.
- WIPO PatentScope database, Patent Family Analysis.
- KIPO Patent Landscape Reports (2022).
- Patent Document Analysis and Classification Systems (IPC, CPC).
- Industry reports on South Korea pharmaceutical patent activity.
This detailed analysis illuminates the strategic importance of KR20170126016 within Korea’s pharmaceutical patent ecosystem—guiding stakeholders in making informed, strategic decisions to optimize intellectual property assets.
